RA
TXG icon

Rise Advisors’s 10x Genomics TXG Stock Holding History

Rise Advisors’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-114
Closed -$1.33K – 1327
2025
Q3 		$1.33K Hold
114
– – ﹤0.01% 1236
2025
Q2 		$1.32K Buy
+114
New +$1.04K ﹤0.01% 1246
2023
Q3 		– Sell
-11
Closed -$614 – 696
2023
Q2 		$614 Hold
11
– – ﹤0.01% 605
2023
Q1 		$614 Hold
11
– – ﹤0.01% 719
2022
Q4 		$401 Hold
11
– – ﹤0.01% 721
2022
Q3 		$0 Hold
11
– – ﹤0.01% 748
2022
Q2 		$0 Hold
11
– – ﹤0.01% 737
2022
Q1 		$1K Hold
11
– – ﹤0.01% 641
2021
Q4 		$1.64K Buy
+11
New +$1.69K ﹤0.01% 556

Other funds holding TXG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Rise Advisors's TXG Position: Q4 2025 in Review

Rise Advisors sold out of 10x Genomics (TXG) in Q4 2025, closing a stake of 114 shares — an estimated $1.33K sold.

Rise Advisors first reported a position in TXG in Q4 2021 and held it in 9 quarters. The position peaked at $1.64K in Q4 2021. 322 funds tracked by Wall St. Rank hold TXG as of Q4 2025.

  • Rise Advisors reported no remaining 10x Genomics position as of Q4 2025 after selling out during the quarter.
  • Rise Advisors sold 114 10x Genomics shares in Q4 2025, an estimated $1.33K.
  • Rise Advisors first reported a position in 10x Genomics in Q4 2021 and held it in 9 quarters.
  • Rise Advisors's 10x Genomics position peaked at $1.64K in Q4 2021.
  • 322 funds tracked by Wall St. Rank held 10x Genomics as of Q4 2025.

Based on Rise Advisors's 13F filing for Q4 2025, filed 11 Feb 2026.